Pfizer to start selling Remicade biosimilar in US next month

18 October 2016

US pharma major Pfizer (NYSE: PFE) has announced it will begin selling its biosimilar of blockbuster rheumatoid-arthritis treatment Remicade in the USA at a 15% discount by the end of November.

Inflectra (infliximab-dyyb), approved by the US Food and Drug Administration (FDA) earlier this year, will be the first biosimilar monoclonal antibody (MAb) and only the second biosimilar available in the USA.

It follows the results of the NOR-SWITCH study, announced at the United European Gastroenterology Week earlier today, which demonstrated that switching from Remicade to Inflectra was not inferior to continued treatment with Remicade.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK